Owkin

🚀 Owkin Launches K Pro at ESMO 2025! We’re unveiling K Pro – the first agentic AI co-pilot for biopharma powered by advanced biological reasoning models. K Pro is built on 10 years of Owkin’s AI innovation. It empowers pharma, biotech, and investors to make smarter, faster decisions across the R&D pipeline. K Pro combines: • Natural language interaction for querying complex biological questions • High-quality, multimodal biomedical data – curated, integrated, and AI-ready • Agentic AI that delivers, analysis, visualizations, and actionable clinical insights in moments, not months At its core, K Pro integrates OwkinZero - our pioneering biological large language model to perform high-level biological reasoning - and unifies fragmented workflows for both scientists and executives. Find the press release here: owkin.com/newsfeed/owkin… 🔗 Visit us at ESMO booth #4021 to learn more about how K Pro is changing the game for biopharma decision-making or book a meeting with our team here: calendly.com/esmo-2025

As part two of our Woman in Tech Spotlight Series, we’re featuring our Head of Platform Biology, @ Roberta Codato, who shares a powerful reminder: your voice matters. Follow along as we continue to highlight the women shaping Owkin!

Preprint on bioRxiv: 1st comprehensive multi-modal benchmark of Ultima UG100 vs Illumina NovaSeq on FFPE tissues. Preprint: biorxiv.org/content/10.648… Code: github.com/owkin/ultilumi…

We just trained an AI to come up with novel therapeutic hypotheses, and it outperformed GPT-5. Find out more in our blog: owkin.com/blogs-case-stu…

🚀 Join us at Start Summit this week Our Chief Medical Officer, Dr. Caroline Hoffmann, will sit down with Dr. Friederike Hoffmann, Partner at b2venture, for a fireside chat on “Prompt. Protein. Patient.” 🔎 Learn more: startglobal.org/start-summit

🎙️ We continue our sit down session with our Chief Research & Development Officer Eric Durand to understand Owkin’s K Pro infrastructure, as well as our ongoing work building our AI scientist. Learn more about K Pro: owkin.com/k-os/k-pro

🎙️ We sit down with our Chief Research & Development Officer Eric Durand to get his take on how we achieve biological artificial superintelligence, the technology that will drive this shift and how Owkin’s is developing it.

🔬 We're partnering with @ConsensusNLP - the leading AI-powered scientific paper research engine - to bring 200 million peer-reviewed papers directly into K Pro: our AI scientist for biology. Read the press release: owkin.com/newsfeed/owkin…

✨ Excited to share Owkin’s new multi-year partnership with NHS Lothian to help build the foundations for next-generation agentic AI in drug discovery and diagnostics. 👉 Read the press release: owkin.com/newsfeed/nhs-l…

📢 Our CEO @TClozel, will be speaking at Health.Tech Global Summit 2026 📅 March 3, 2026 | 🕐 11:30am-12:00 pm CET in Basel, Switzerland To learn more and to register visit health.tech

Caroline, Chief Med Officer, is exploring data from our INVOKE Phase 1 clinical trial in ways not possible before. Using AI capabilities we're building into K Pro, she can interrogate data in real time to refine patient populations & identify biomarkers that inform trial design.

🤖 We built a tool to solve a problem we kept running into: spending days trying to reproduce bioinformatic and computational biology methods from papers. Paper-to-Skills extract methodologies from papers & turns it into executable skills for Claude Code: paper2skills.com/?utm_source=li…

Use Owkin’s Paper-to-Skills app to extract methodologies & techniques from papers and generate skills for Claude - in minutes. • Upload paper • Extract methodologies • Convert into skills • Run in Claude Code Create your first skill now: paper2skills.com/?utm_source=x&…

Our Chief Transformation Officer Andrea Tassistro, will be speaking at La santé: vers une possible gouvernance européenne, co-hosted by Pergamon and APM International in Paris. Register now: eventbrite.com/e/la-sante-ver…

💡 “Imagine the ideal healthcare system…” Alex Zhavoronkov brings the big ideas talking to Thomas Clozel in our recent podcast, covering how AI is changing pharma and what it takes to make it in AI healthcare. 25 mins long. Watch here. youtube.com/watch?v=ONVivM…

🎤 “I think OpenAI, Anthropic, other companies are going to have assets soon as well.” “BINGO” Thomas Clozel sits down with Insilico Medicine Alex Zhavoronkov to discuss the hospital of the future and the entry of big tech players AI in healthcare. youtube.com/watch?v=ONVivM…

🎤 Thomas Clozel sits down with Insilico Medicine CEO Alex Zhavoronkov in the first of our Owkin podcasts where we talk to leaders in AI, Biotech and Pharma about the changing world of AI in healthcare. 25 mins long. Watch here. youtu.be/ONVivM-4mgo

Our Deputy CEO Pascal Weinberger will be speaking at the 2026 Lake Nona Innovation Forum on Feb 27, Orlando. Panel: "Code Blue: When Tech Rewrites Medicine". Learn how Owkin is building AI to transform drug development and rewrite the future of medicine at owkin.com

🇫🇷 Our Chief R&D Officer Eric Durand in @LesEchos, discussing our partnerships with Anthropic and Nvidia 🏥 "AI has unlocked unprecedented capabilities in the healthcare field. AI is expanding its scope." The future of healthcare AI is here. Read more: lesechos.fr/tech-medias/in…

We'll be at #AUTM2026 in Seattle, Feb 8-11 🌟connecting with academic & industry leaders shaping the future of tech transfer. If you're thinking about unlocking your institution's data while advancing medicine, let's talk. Learn more: owkin.com/our-events/aut…

Published in Nature Communications: MISO predicts spatial transcriptomics at near single-cell resolution from H&E slides alone. In collaboration with @ffcd_cancerdig. Thanks to MOSAIC partners for the data gen. Paper: nature.com/articles/s4146… Code: github.com/owkin/miso_code